myelodysplastic syndromes (MDS) | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality

Author(s): 
A Sutra Del Galy, A Marouf, E Raffoux, M Robin, D Michonneau, M Sébert, F Sicre de Fontebrune, A Xhaard, E Lengline, R Itzykson, C Frieri, H Dombret, P Fenaux, R Peffault de Latour, L Adès, G Socié
Primary Author: 
A Sutra Del Galy
Journal Title: 
Leukemia
Original Publication Date: 
Jul 2020
Bone Marrow Diseases: 

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients

Author(s): 
Valeria Santini, Pierre Fenaux, Aristoteles Giagounidis, Uwe Platzbecker, Alan F List, Torsten Haferlach, Jim Zhong, Chengqing Wu, Konstantinos Mavrommatis, C L Beach, Kyle J MacBeth, Antonio Almeida
Primary Author: 
Santini, V
Journal Title: 
Leukemia
Original Publication Date: 
Jul 2020
Bone Marrow Diseases: 

Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

Author(s): 
Anna M Tanasijevic, Anna Revette, Heidi D Klepin, Amer Zeidan, Danielle Townsley, Courtney D DiNardo, Marie Sebert, Amy E DeZern, Richard M Stone, Emily S Magnavita, Richard Chen, Mikkael A Sekeres, Gregory A Abel
Primary Author: 
Tanasijevic, AM
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Jul 2020

The

Bone Marrow Diseases: 

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Author(s): 
Elsa Bernard, Yasuhito Nannya, Robert P Hasserjian, Sean M Devlin, Heinz Tuechler, Juan S Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max F Levine, Juan E Arango, Yangyu Zhou, Francesc Sole, Catherine A Cargo
Primary Author: 
Bernard, E
Journal Title: 
Nature Medicine
Original Publication Date: 
Aug 2020

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with

Bone Marrow Diseases: 

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

Author(s): 
Justin Taylor, Xiaoli Mi, Alexander V Penson, Stella V Paffenholz, Kelsey Alvarez, Allison Sigler, Stephen S Chung, Raajit K Rampal, Jae H Park, Eytan M Stein, Martin S Tallman, Filiz Sen, Mithat Gönen, Omar Abdel-Wahab, Virgin M Klimek
Primary Author: 
Taylor, J
Journal Title: 
Lancet Hematology
Original Publication Date: 
Aug 2020

Background: The median overall survival of patients with high-risk

Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival

Author(s): 
Erel Joffe, Uri Greenbaum, Gili Man-El, Kalman Filanovsky, Howard S Oster, Itai Levi, Pia Raanani, Irit Avivi, Moshe Mittelman
Primary Author: 
Joffe, E
Journal Title: 
Hematological Oncology
Original Publication Date: 
Jul 2020

We reviewed pre-diagnosis clinical data of 420 patients with pathologically confirmed

Bone Marrow Diseases: 

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Author(s): 
David A Sallman, Amy F McLemore, Amy L Aldrich, Rami S Komrokji, Kathy L McGraw, Abhishek Dhawan, Susan Geyer, Hsin-An Hou, Erika Adriana Eksioglu, Amy Sullivan, Sarah Warren, Kyle J MacBeth, Manja Meggendorfer, Torsten Haferlach
Primary Author: 
Sallman DA
Journal Title: 
Blood
Original Publication Date: 
Jul 2020

Somatic gene mutations are key determinants of outcome in patients with